CL2007001602A1 - Uso de un inhibidor de dimerizacion del receptor her para tratar cancer que produce altos niveles del factor de crecimiento epidermico (egf) o del factor de crecimiento transformador alfa (tgf-alfa). - Google Patents

Uso de un inhibidor de dimerizacion del receptor her para tratar cancer que produce altos niveles del factor de crecimiento epidermico (egf) o del factor de crecimiento transformador alfa (tgf-alfa).

Info

Publication number
CL2007001602A1
CL2007001602A1 CL200701602A CL2007001602A CL2007001602A1 CL 2007001602 A1 CL2007001602 A1 CL 2007001602A1 CL 200701602 A CL200701602 A CL 200701602A CL 2007001602 A CL2007001602 A CL 2007001602A CL 2007001602 A1 CL2007001602 A1 CL 2007001602A1
Authority
CL
Chile
Prior art keywords
alfa
growth factor
egf
tgf
receiver
Prior art date
Application number
CL200701602A
Other languages
English (en)
Inventor
C Amier Nusrat Rabee And Lukas
Original Assignee
Genentech Inc F Hoffmann La Ro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc F Hoffmann La Ro filed Critical Genentech Inc F Hoffmann La Ro
Publication of CL2007001602A1 publication Critical patent/CL2007001602A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CL200701602A 2006-06-05 2007-06-05 Uso de un inhibidor de dimerizacion del receptor her para tratar cancer que produce altos niveles del factor de crecimiento epidermico (egf) o del factor de crecimiento transformador alfa (tgf-alfa). CL2007001602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81123406P 2006-06-05 2006-06-05

Publications (1)

Publication Number Publication Date
CL2007001602A1 true CL2007001602A1 (es) 2008-03-14

Family

ID=38691718

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200701602A CL2007001602A1 (es) 2006-06-05 2007-06-05 Uso de un inhibidor de dimerizacion del receptor her para tratar cancer que produce altos niveles del factor de crecimiento epidermico (egf) o del factor de crecimiento transformador alfa (tgf-alfa).

Country Status (13)

Country Link
US (1) US20080038271A1 (es)
EP (1) EP2035039A2 (es)
JP (1) JP2009539836A (es)
KR (1) KR20090019890A (es)
CN (1) CN101495142A (es)
AR (1) AR061230A1 (es)
AU (1) AU2007259171A1 (es)
BR (1) BRPI0712077A2 (es)
CA (1) CA2654584A1 (es)
CL (1) CL2007001602A1 (es)
MX (1) MX2008015581A (es)
TW (1) TW200815472A (es)
WO (1) WO2007145862A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
JP5623743B2 (ja) * 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN106153918A (zh) * 2008-10-14 2016-11-23 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
CA2751888C (en) * 2009-02-11 2022-06-14 Caris Mpi, Inc. Molecular profiling of tumors
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
RU2016105962A (ru) * 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
CN104725509B (zh) * 2010-05-18 2018-12-18 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
EP2596359A1 (en) * 2010-07-19 2013-05-29 F.Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500848B1 (de) * 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor

Also Published As

Publication number Publication date
AR061230A1 (es) 2008-08-13
WO2007145862A2 (en) 2007-12-21
TW200815472A (en) 2008-04-01
MX2008015581A (es) 2008-12-17
US20080038271A1 (en) 2008-02-14
KR20090019890A (ko) 2009-02-25
EP2035039A2 (en) 2009-03-18
BRPI0712077A2 (pt) 2012-01-17
WO2007145862B1 (en) 2008-05-02
JP2009539836A (ja) 2009-11-19
WO2007145862A3 (en) 2008-02-28
CN101495142A (zh) 2009-07-29
CA2654584A1 (en) 2007-12-21
AU2007259171A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
CL2008000614A1 (es) Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
AR061230A1 (es) Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa
CR20110526A (es) Anticuerpos anti - tnf - alfa y sus usos
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
CL2008002397A1 (es) Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna.
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
EA201171367A1 (ru) Винилиндазолильные соединения
CR20130071A (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (her 3)
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
CR9301S (es) Cuerpo de grifo
CL2012002252A1 (es) Conjunto antidesgaste que incluye un elemento antidesgaste que va a montarse en un implemento o aparato que va a protegerse, un elemento de base que va a acoplarse al implemento o aparato, un elemento de bloqueo para bloquear dicho elemento antidesgaste con respecto a dicho elemento de base; base para un conjunto antidesgaste; bloqueo ; elemento de bloqueo; conjunto antidesgaste.
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
CL2008000793A1 (es) Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX380512B (es) Formulación de revestimiento para madera.
CR20120204A (es) Nuevo uso antitumoral de cabazitaxel
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
CL2008000441A1 (es) Anticuerpo especifico para el receptor del factor de crecimiento similar a insulina (igf-1r) o fragmento de union a antigeno del mismo; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
PH12012501459A1 (en) Lightweight cement board
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
MX2010001578A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001579A (es) Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
CL2007000775A1 (es) Uso de compuestos derivados de benzofurano para el tratamiento de un desorden cognitivo.
DE502008001955D1 (en) Textile gefässprothese